

Supplementary Table S1. Treatment decision (n = 212)

Influencing factors to induce a certain therapy, mean \pm SD (range)	
(1=low priority, 5=very high priority)	
Free of relapses (n=178)	4.8 \pm 0.6 (1–5)
Delaying the grade of disability (n=182)	4.7 \pm 0.7 (1–5)
Efficacy (n=168)	4.7 \pm 0.8 (1–5)
Self-dependence (n=163)	4.6 \pm 0.9 (1–5)
Long-term safety profile of the therapy (n=167)	4.3 \pm 1.0 (1–5)
Tolerance of the drugs (n=165)	4.1 \pm 1.2 (1–5)
Partnership (n=155)	4.1 \pm 1.3 (1–5)
Job (n=154)	4.0 \pm 1.3 (1–5)
Others (n=23)	3.7 \pm 1.7 (1–5)
Documented long-term data of the drugs (n=145)	3.6 \pm 1.3 (1–5)
Frequency of drug-usage (n=157)	3.4 \pm 1.5 (1–5)
Type of drug application (n=163)	3.4 \pm 1.5 (1–5)
Family planning (n=147)	2.6 \pm 1.7 (1–5)
Influence of Side effects on treatment decision, mean \pm SD	
(range) (1 = not at all; 5 = very high)	
Cardiac arrhythmia	2.3 \pm 1.6 (1–5)
Macular edema	2.3 \pm 1.6 (1–5)
Injection site reaction	2.9 \pm 1.5 (1–5)
Thinning of the hair	2.3 \pm 1.6 (1–5)
Infections	2.7 \pm 1.6 (1–5)
Progressive multifocal Leukoencephalopathy (PML)	2.8 \pm 1.8 (1–5)
Nausea and vomiting	2.6 \pm 1.5 (1–5)
Skin rash and flush	2.8 \pm 1.5 (1–5)
Lymphopenia	2.2 \pm 1.5 (1–5)
Fatigue	3.1 \pm 1.5 (1–5)
Flu like symptoms	3.1 \pm 1.5 (1–5)
Risk for cancer	2.7 \pm 1.7 (1–5)
Constipation	2.6 \pm 1.5 (1–5)
Current data during pregnancy	2.0 \pm 1.6 (1–5)
Safety feeling with regard to therapeutic decision (n= 196)	
1 (very safe)	44 (22.4%)
2	40 (20.4%)
3	60 (30.6%)
4	35 (17.9%)
5 (very unsafe)	17 (8.7%)
n, number; CIS, clinically isolated syndrome; RRMS, relapsing remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis	

Supplementary Table S2. Treatment satisfaction

Satisfaction with current therapy (n = 190)	
1 (very satisfied)	111 (58.4%)
2	35 (18.4%)
3	27 (14.2%)
4	10 (5.3%)
5 (not at all satisfied)	7 (3.7%)
missing	2 (1.1%)
Satisfaction with current medical care (n = 201)	
1 (very satisfied)	116 (57.7%)
2	48 (23.9%)
3	17 (8.5%)
4	14 (7.0%)
5 (not at all satisfied)	6 (3.0%)
Would you in retrospect choose the same initial therapy	
Yes	128 (60.4%)
No	56 (26.4%)
Missing	28 (13.2%)
Current quality of life (n = 206)	
1 (very good)	70 (34.0%)
2	62 (30.1%)
3	48 (23.3%)
4	20 (9.7%)
5 (very bad)	6 (2.9%)

n, number; CIS, clinically isolated syndrome; RRMS, relapsing remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis